Drotrecogin alfa (activated) in adults with septic shock Academic Article uri icon

Overview

MeSH Major

  • Anti-Infective Agents
  • Protein C
  • Shock, Septic

abstract

  • DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock. (Funded by Eli Lilly; PROWESS-SHOCK ClinicalTrials.gov number, NCT00604214.).

publication date

  • May 31, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1202290

PubMed ID

  • 22616830

Additional Document Info

start page

  • 2055

end page

  • 64

volume

  • 366

number

  • 22